Atypical femoral fractures – what´s new?

Download PDF Czech version

Authors: Franeková Lenka
Authors‘ workplace: Interní klinika – revmatologická a osteologická ambulance 1. LF UK a ÚVN – Vojenská fakultní nemocnice Praha
Published in: Clinical Osteology 2021; 26(4): 191-199
Category:

Overview

Atypical femoral fracture (AFF) is defined as an atraumatic or low stress fracture located between the subtrochanteric and supracondylar area of the femur, with typical clinical and radiological features. These factures are most often considered a complication of long-term treatment using bisphosphonates and denosumab, also occurring more often during treatment using glucocorticoids and proton-pump inhibitors. Determination of an atypical femoral fracture continues to be governed by the revised criteria of the ASBMR (American Society of Bone and Mineral Research) published in 2014. Assessment of the specificity of individual radiological criteria has shown that the transversal orientation of the fracture of the lateral cortex is crucial. Subsequent progress of the fracture line should be transversal or oblique. At our facility we have also documented the case of a female patient with a spiral fracture, which met ASBMR criteria for an atypical femoral fracture. ASBMR criteria for AFF exclude periprosthetic fractures, despite orthopaedic facilities pointing out the existence of periprosthetic fractures, which have the characteristics of would meet radiological criteria for atypical femoral fracture and also occur more frequently in patients taking bisphosphonates. The prevalence of these types of fractures among periprosthetic fractures ranges between 8–10 %. The risk of these atypical periprosthetic fractures increases as the duration of use of bisphosphonates increases. The possibility of genetic predisposition for origin of atypical femoral fractures can be considered in persons who have not taken any risk medication of such fractures. The cause may also be genetically dependent bone disorders, which are accompanied by pseudofractures very similar to atypical fractures. This article also discuses other accessory risk factors of AFF and recommendations for therapy.

Keywords:

teriparatide – bisphosphonates – denosumab – atypical femoral fractures – periprosthetic fractures

Sources

Marshall RA, Mandell JC, Weaver MJ et al. Imaging features and management of stress, atypical, and pathologic fractures. RadioGraphics 2018; 38(7): 2173–2192. Dostupné z DOI: <http://dx.doi. org/10.1148/rg.2018180073>.
Png MA, Mohan PC, Koh J et al. Natural history of incomplete atypical femoral fractures in patients after a prolonged and variable course of bisphosphonate therapy – a long- term radiological follow- -up. Osteoporos Int 2019; 30(12): 2417–2428. Dostupné z DOI: <http:// dx.doi.org/10.1007/s00198–019–05067–7>.
Shane E, Burr D, Abrahamsen B et al. Atypical subtrochanteric and diaphyseal femoral fractures: Second report of task force of the American society for bone and mineral research. J Bone Miner Res 2014; 29(1): 1–23. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.1998>.
Adams AL, Xue F, Chantra JQ et al. Sensitivity and specificity of radiographic characteristics in atypical femoral fractures. Osteoporos Int 2017; 28(1): 413–417. Dostupné z DOI: <http://dx.doi.org/10.1007/ s00198–016–3809-y>
LeBlanc ES, Rosales AG, Genant HK et al. Radiological criteria for atypical features of femur fractures: what we can learn when applied in a clinical study setting. Osteoporos Int 2019; 30(6): 1287–1295. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–019–04869-z>.
Tomonori B, Masataka U, Hironori O et al. Atypical periprosthetic femoral fractures after arthroplasty for fracture are at high risk of complications. Sci Rep 2021; 11(1):14378. Dostupné z DOI: <http:// doi: 10.1038/s41598-021-93574-1>.
Leclerc JT, Michou L, Vaillancourt F et al. Prevalence and characteristics of atypical periprosthetic femoral fractures. J Bone Miner Res 2019; 34(1): 83–92. Dostupné z DOI: <http://dx.doi.org/10.1002/ jbmr.3584>.
MacKenzie SA, Ng RT, Snowden G et al. Periprosthetic atypical femoral fractures exist and are associated with duration of bisphosphonate therapy. Bone Joint J 2019; 101-B(10): 1285–1291. Dostupné z DOI: <http://dx.doi.org/10.1302/0301–620X.101B10.BJJ-2019– 0599.R2>.
Dózsai D, Ecseri T, Csonka I et al. Atypical periprosthetic femoral fracture associated with long-term bisphosphonate therapy. J Orthop Surg Res 2020; 15(1): 414–420. Dostupné z DOI: <http://dx.doi. org/10.1186/s13018–020–01941-x>.
Simoes ND, Goncalves Z, Moreno J et al. Peri-implant atypical fractures associated with bisphosphonates: Should this clinical entity be included in the definition of atypical femoral fracture? Case report. J Orthop Case Rep 2018; 8(4): 66–69. Dostupné z DOI: <http://dx.doi. org/10.13107/jocr.2250–0685.1164>.
Gedmintas L, Solomon DH, Kim SC. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res 2013; 28(8): 1729– 1737. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.1893>.
Adler RA, Fuleihan GE, Bauer DC et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: Report of a task force of the American society for bone and mineral research. J Bone Miner Res 2016; 31(1): 16–35. Dostupné z DOI: <http://dx.doi. org/10.1002/jbmr.2708>.
Dell R, Greene D. A proposal for an atypical femur fracture treatment and prevention clinical practice guideline. Osteoporosis Int 2018; 29(6):1277–1283. Dostupné z DOI: <http://dx.doi.org/10.1007/ s00198–018–4506–9>.
Guanabens N, Moro-Álvarez MJ, Casado E et al. The next step after anti-osteoporotic drug discontinuatio: an up-to-date review of sequential treatment. Endocrine 2019; 64(3): 441–455. Dostupné z DOI: <http://dx.doi.org/10.1007/s12020–019–01919–8>.
Allison MB, Markman L, Rosenberg Z et al. Atypical incomplete femoral fractures in asymptomatic patients on long term bisphosphonate therapy. Bone 2013; 55(1): 113–118. Dostupné z DOI: <http:// dx.doi.dorg/10.1016/j.bone.2013.03.018>.
Schilcher J, Michaëlsson K, Aspenberg P et al. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011; 364(18): 1728–1737. Dostupné z DOI: <http://dx.doi.org/10.1056/ NEJMoa1010650>
Schilcher J, Koeppen V, Aspenberg P et al. Risk of atypical femoral fracture during and after bisphosponate use. Acta Orthop 2015; 8(1): 100–107. Dostupné z DOI: <http://dx.doi.org/10.3109/17453674.2015 .1004149>.
Dennison EM, Cooper C, Kanis JA et al. Fracture risk following intermission of osteoporosis therapy. Osteoporosis Int 2019; 30(9): 1733–1743. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198– 019–05002-w>.
Smith MD, Haseman OJ, Garza JAV et al. Bilateral atypical fractures of the femur: ten years after ten years of bisphosponate therapy. Bone Rep 2021; 15:101112. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bonr.2021.101112>.
Gun-Il I, Seung-Hyo J. Pathogenesis, management and prevention of atypical femoral fractures. J Bone Metab 2015; 22(1): 1–8. Dostupné z DOI: <http://dx.doi.org/10.11005/jbm.2015.22.1.1>.
Bögl HP, Aspenberg P, Schilcher J. Undisturbed local bone formation capacity in patients with atypical femoral fractures: a case series. Osteoporosis Int 2017; 28(8): 2439–2444. Osteoporosis Int 2017; 28(8): 2439–2444. Dostupné z DOI: <http://dx.doi.org/10.1007/ s00198–017–4058–4>.
Rasmussen NH, Dal J, Vries F et al. Diabetes and fractures? new evidence of atypical femoral fractures. Osteoporosis Int 2020; 31(3): 447–455. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–019– 05224-y>.
Funck-Brentano T, Ostertag A, Debiais F et al. Identification of a p.Arg708Gln variant in COL1A2 in atypical femoral fractures. Joint Bone Spine 2017; 84(6): 715–718. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jbspin.2016.11.014>.
Nguyen HH, Laarschot DM, Verkerk AJ. Genetic risk factors for atypical femoral fractures (AFFs): a systematic review. JBMR Plus 2018; 2(1): 1–11. Dostupné z DOI: <http://dx.doi.org/10.1002/jbm4.10024>.
Andersen JD, Bünger MH, Rahbek O et al. Do femoral fractures in adult patients with osteogenesis imperfecta imitate atypical femoral fractures? A case series. Osteoporosis Int 2019; 30(2): 513–517. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–018–4769–1>.
Romans M, Sambandan B, Moses J et al. A rare case of pycnodysostosis: technical difficulties in managing long bone fractures. J Clin Orthop Trauma 2020; 11(2): 332–338. Dostupné z DOI: <http://dx.doi. org/10.1016/j.jcot.2018.09.012>.
Wu CC, Econs MJ, DiMeglio LA et al. Diagnosis and management of osteopetrosis: consensus guidelines from the osteopetrosis working group. J Clin Endocrinol Metab 2017; 102(9): 3111–3123. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2017–01127>.
Laarschot DM, McKenna MJ, Abrahamsen B et al. Medical management of patients after atypical femur fractures: a systematic review and recommendations from the European Calcified Tissue Society 2020. J Clin Endocrinol Metab 2020; 105(5): 1682–1699. Dostupné z DOI: <http://dx.doi.org/10.1210/clinem/dgz295>

Labels

Clinical biochemistry Paediatric gynaecology Paediatric radiology Paediatric rheumatology Endocrinology Gynaecology and obstetrics Internal medicine Orthopaedics General practitioner for adults Radiodiagnostics Rehabilitation Rheumatology Traumatology

Osteoporosis care during the COVID-19 pandemic

Bone mineral content, subcutaneous and visceral adipose tissue volumetric measurements: A pilot study in routine computed tomography examinations

Latest research and news in osteology

Supplementing of the Abstract Book: XXIVth Congress of Czech and Slovak Osteologists

Article was published in

Clinical Osteology

2021 Issue 4